Date
A letter has been released regarding the change of available products on the Canadian Blood Services formulary for the care of patients requiring subcutaneous immune globulin (Ig) therapy. As the inventory of Hizentra will soon be depleted, it is important that patients be transitioned to Cuvitru as quickly as possible.
For further details and contact information, please view the letter or visit www.blood.ca.